C-C Chemokine Receptor 2 and C-C Chemokine Receptor 5 Genotypes in Patients Treated for Chronic Hepatitis C Virus Infection

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2002 Oct 31

PMID 12403355

Citations 2

Authors

M Tevfik Dorak

Gbolahan O Folayan

Santosh Niwas

Dirk J van Leeuwen

Leland J Yee

Jianming Tang

Richard A Kaslow

Affiliations

Soon will be listed here.

Abstract

We explored the influence of the major CCR5 promoter or coding region variants as haplotypes and genotypes in a cohort of 250 chronically infected HCV patients receiving combined interferon/ ribavirin therapy. No haplotype, including the D32-bearing haplotype (G*2) reportedly associated in homozygotes with high HCV viral load (VL), showed a similar effect. Patients with genotype C/G*2 showed slightly lower median VL (p = 0.05). Neither the G*2 haplotype nor the C/G*2 genotype influenced viral dynamics during the initial 12 wk of treatment (p = 0.53). The genotype E/E was more frequent among sustained responders (15.5%) than non-responders (7.8%), and VL declined further among E/E homozygotes during the initial 12 wk of treatment, particularly those with HCV genotype 1 (p = 0.016). Differential receptor expression due to E/E homozygosity in HCV infection remains to be confirmed.

Citing Articles

CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug users.

Huik K, Avi R, Carrillo A, Harper N, Pauskar M, Sadam M PLoS One. 2013; 8(7):e70561.

PMID: 23936229 PMC: 3723663. DOI: 10.1371/journal.pone.0070561.

CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.

Montes-Cano M, Garcia-Lozano J, Aguilar-Reina J, Romero-Gomez M, Barroso N, Nunez-Roldan A World J Gastroenterol. 2007; 13(15):2187-92.

PMID: 17465499 PMC: 4146842. DOI: 10.3748/wjg.v13.i15.2187.

References

Jonsson J, Purdie D, Bansal A, Shorthouse C, Powell E . Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999; 30(2):526-30. DOI: 10.1002/hep.510300207. View

Dean M, Carrington M, Winkler C, Huttley G, Smith M, Allikmets R . Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort,.... Science. 1996; 273(5283):1856-62. DOI: 10.1126/science.273.5283.1856. View

Powell E, Hay J, Clouston A, Crawford D, Shorthouse C, Purdie D . Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000; 31(4):828-33. DOI: 10.1053/he.2000.6253. View

McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339(21):1485-92. DOI: 10.1056/NEJM199811193392101. View

Carrington M, Nelson G, Martin M, Kissner T, Vlahov D, Goedert J . HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999; 283(5408):1748-52. DOI: 10.1126/science.283.5408.1748. View

Tang J, Rivers C, Karita E, Costello C, Allen S, Fultz P . Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression. Genes Immun. 2001; 1(1):20-7. DOI: 10.1038/sj.gene.6363640. View

Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A . Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis. 2001; 183(11):1574-85. DOI: 10.1086/320705. View

Thursz M . Host genetic factors influencing the outcome of hepatitis. J Viral Hepat. 1997; 4(4):215-20. DOI: 10.1046/j.1365-2893.1997.00052.x. View

Yee L, Tang J, Gibson A, Kimberly R, van Leeuwen D, Kaslow R . Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology. 2001; 33(3):708-12. DOI: 10.1053/jhep.2001.22347. View

10.

Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G . Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group.... Lancet. 1998; 352(9138):1426-32. DOI: 10.1016/s0140-6736(98)07124-4. View

11.

McNicholl J, Downer M, Udhayakumar V, Alper C, Swerdlow D . Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu Rev Public Health. 2000; 21:15-46. DOI: 10.1146/annurev.publhealth.21.1.15. View

12.

Alric L, Fort M, Izopet J, Vinel J, Bureau C, Sandre K . Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens. 2000; 56(2):154-8. DOI: 10.1034/j.1399-0039.2000.560207.x. View

13.

Libert F, Cochaux P, BECKMAN G, Samson M, Aksenova M, Cao A . The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet. 1998; 7(3):399-406. DOI: 10.1093/hmg/7.3.399. View

14.

Yoshie O, Imai T, Nomiyama H . Chemokines in immunity. Adv Immunol. 2001; 78:57-110. DOI: 10.1016/s0065-2776(01)78002-9. View

15.

Yee L, Tang J, Herrera J, Kaslow R, van Leeuwen D . Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun. 2001; 1(6):386-90. DOI: 10.1038/sj.gene.6363696. View

16.

Zein N . Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2001; 13(2):223-35. PMC: 100152. DOI: 10.1128/CMR.13.2.223. View

17.

Lauer G, Walker B . Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-52. DOI: 10.1056/NEJM200107053450107. View

18.

Cooke G, Hill A . Genetics of susceptibility to human infectious disease. Nat Rev Genet. 2001; 2(12):967-77. DOI: 10.1038/35103577. View

19.

Neumann A, Lam N, Dahari H, Davidian M, Wiley T, Mika B . Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000; 182(1):28-35. DOI: 10.1086/315661. View

20.

Yee L, Weiss H, Langner R, Herrera J, Kaslow R, van Leeuwen D . Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infect Dis. 2001; 1:8. PMC: 37546. DOI: 10.1186/1471-2334-1-8. View